P A T E N T
USSN 09/\_\_\_\_\_
Atty Dkt: 0207-0007

Figure 1: Specific Ab Levels (IgG) in Visceral Leishmaniasis Patients



5




Figure 2: Specific Ab Levels (IgM) in Visceral Leishmaniasis Patients




Figure 3: Specific Ab Levels (IgG) Cutaneous Leishmaniasis




Figure 4: Specific Ab Levels (IgM) in Cutaneous Leishmaniasis Patients




Figure 5: Specific Ab Levels (IgG) in Canines Infected with *L. chagasi* 





Figure 6: Specific Ab Levels (IgM) in Canines Infected with *L. chagasi* 








Figure 7: Western blot showing specific activity of Nabbit anti-leishmania PAb, normal human sera and sera from kala azar patients.



- Ag Inc / HRP-Ag HRP-Ag Inc / Ag

Figure 8: Graph Depicting Specific Activity of the Competitive Ag-Capture ELISA Using Different Antigen and HRP-Labeled Antigen Conditions.

HRP-Ag Inc



--- Coated/Blocked
--- Noncoated/ Blocked
--- Noncoat/Nonblock

Figure 9: Graph Depicting Specific Activity of the Competitive Ag-Capture ELISA While Titrating Labeled Antigen Under Different Coating and Blocking Conditions